La Jolla Pharmaceutical Company was granted Breakthrough Therapy designation by the FDA for the New Investigational Drug Product, LJPC-0118, for the treatment of severe malaria. The Breakthrough Therapy designation aims to expedite the development and review of drugs intended to treat serious or life-threatening conditions. To qualify, preliminary clinical evidence must demonstrate substantial improvement over currently available therapy on at least one clinically significant endpoint. “We...